Top-News
Pharmazeutika Norwegen

CIRCIO HOLDING News

Aktie
WKN:  A3EUN9 ISIN:  NO0013033795
0,1835 €
+0,0075 €
+4,26%
21.05.24 16:06:24
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

CIRCIO HOLDING News

01.07.21 - PR Newswire
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer PR Newswire
01.07.21 - PR Newswire
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer PR Newswire
28.06.21 - PR Newswire
Targovax to present at the 4th Annual Next Gen Immuno-oncology Virtual Congress-US Edition
Targovax to present at the 4th Annual Next Gen Immuno-​oncology Virtual Congress-​US Edition PR Newswire
28.06.21 - PR Newswire
Targovax to present at the 4th Annual Next Gen Immuno-oncology Virtual Congress-US Edition
Targovax to present at the 4th Annual Next Gen Immuno-​oncology Virtual Congress-​US Edition PR Newswire
10.06.21 - PR Newswire
Targovax's ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
Targovax's ONCOS-102 mesothelioma 24-month data shows class-​leading median overall survival - Median overall survival (mOS) for first-​line treatment with ONCOS-102 plus ...
21.05.21 - PR Newswire
Targovax to present at upcoming investor and scientific conferences
Targovax to present at upcoming investor and scientific conferences PR Newswire
21.05.21 - PR Newswire
Targovax to present at upcoming investor and scientific conferences
Targovax to present at upcoming investor and scientific conferences PR Newswire
06.05.21 - PR Newswire
Targovax ASA: First quarter 2021 results
Targovax ASA: First quarter 2021 results PR Newswire
06.05.21 - PR Newswire
Targovax ASA: First quarter 2021 results
Targovax ASA: First quarter 2021 results PR Newswire
04.03.21 - PR Newswire
Targovax ASA: Registration of share capital increase following exercise of options
Targovax ASA: Registration of share capital increase following exercise of options PR Newswire
04.03.21 - PR Newswire
Targovax ASA: Registration of share capital increase following exercise of options
Targovax ASA: Registration of share capital increase following exercise of options PR Newswire
01.03.21 - PR Newswire
Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital
Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital PR Newswire
23.02.21 - PR Newswire
Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up
Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up Median Overall Survival (mOS) has still not been met for randomized first-​line ...
18.02.21 - PR Newswire
Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021
Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021 PR Newswire
18.02.21 - PR Newswire
Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021
Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021 PR Newswire
15.02.21 - PR Newswire
Targovax receives Fast-Track designation for ONCOS-102
Targovax receives Fast-​Track designation for ONCOS-102 PR Newswire
15.02.21 - PR Newswire
Targovax receives Fast-Track designation for ONCOS-102
Targovax receives Fast-​Track designation for ONCOS-102 - The US FDA grants ONCOS-102 Fast-​Track designation for malignant pleural mesothelioma - Fast-​Track opens the ...
11.02.21 - PR Newswire
Agenda for Targovax's Capital Markets Day 18 February 2021
Agenda for Targovax's Capital Markets Day 18 February 2021 PR Newswire
11.02.21 - PR Newswire
Agenda for Targovax's Capital Markets Day 18 February 2021
Agenda for Targovax's Capital Markets Day 18 February 2021 PR Newswire
10.02.21 - PR Newswire
Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality PR Newswire

Newssuche

Videos

newspaper
17.05.24 -6,64%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »